Legal & General Group Plc Invests $14.55 Million in BioCryst Pharmaceuticals, Inc. $BCRX

Posted by Stanley Muller on Aug 31st, 2026

Legal & General Group Plc purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the second quarter, according to its most recent filing with the SEC. The fund purchased 1,455,514 shares of the biotechnology company’s stock, valued at approximately $14,555,000. Legal & General Group Plc owned about 0.57% of BioCryst Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Royal Bank of Canada lifted its stake in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in BioCryst Pharmaceuticals by 6.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after purchasing an additional 8,517 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 49.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock worth $14,490,000 after purchasing an additional 640,704 shares during the period. Caxton Associates LLP acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of BioCryst Pharmaceuticals by 11.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after purchasing an additional 47,355 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BCRX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Needham & Company LLC cut their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Royal Bank Of Canada cut their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Cantor Fitzgerald lifted their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Finally, Citizens Jmp upped their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Eight investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.60.

Check Out Our Latest Research Report on BCRX

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $9.82 on Monday. The firm has a fifty day moving average of $9.71 and a 200-day moving average of $9.07. The company has a market cap of $2.51 billion, a price-to-earnings ratio of -6.55 and a beta of 0.56. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The business had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company’s revenue for the quarter was up 33.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.15 EPS. Analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current year.

BioCryst Pharmaceuticals Profile

(Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.